Department Of Cardiology, Royal Melbourne Hospital, Australia.
J Cardiovasc Electrophysiol. 2010 May;21(5):489-93. doi: 10.1111/j.1540-8167.2009.01658.x. Epub 2009 Dec 15.
The prevalence of vagal and adrenergic atrial fibrillation (AF) and the success rate of pulmonary vein isolation (PVI) are not well defined. We investigated the prevalence of vagal and adrenergic AF and the ablation success rate of antral pulmonary vein isolation (APVI) in patients with these triggers compared with patients with random AF.
Two hundred and nine consecutive patients underwent APVI due to symptomatic drug refractory paroxysmal AF. Patients were diagnosed as vagal or adrenergic AF if >90% of AF episodes were related to vagal or adrenergic triggers; otherwise, a diagnosis of random AF was made. Clinical, electrocardiogram (ECG), and Holter follow-up was every 3 months in the first year and every 6 months afterward and for symptoms. Of 209 patients, 57 (27%) had vagal AF, 14 (7%) adrenergic AF, and 138 (66%) random AF. Vagal triggers were sleep (96.4%), postprandial (96.4%), late post-exercise (51%), cold stimulus (20%), coughing (7%), and swallowing (2%). At APVI, 94.3% of patients had isolation of all veins. Twenty-five (12%) patients had a second APVI. At a follow-up of 21 +/- 15 months, the percentage of patients free of AF was 75% in the vagal group, 86% in the adrenergic group, and 82% for random AF (P = 0.51).
In patients with PAF and no structural heart disease referred for APVI, vagal AF is present in approximately one quarter. APVI is equally effective in patients with vagal AF as in adrenergic and random AF.
迷走和肾上腺素性心房颤动(AF)的发生率以及肺静脉隔离(PVI)的成功率尚不清楚。我们研究了迷走和肾上腺素性 AF 的发生率以及与随机 AF 患者相比,这些触发因素患者的肺静脉窦隔离(APVI)消融成功率。
209 例因症状性药物难治性阵发性 AF 而接受 APVI 的连续患者。如果 >90%的 AF 发作与迷走或肾上腺素能触发因素有关,则诊断为迷走或肾上腺素能 AF;否则,诊断为随机 AF。临床、心电图(ECG)和动态心电图(Holter)随访在第一年每 3 个月一次,之后每 6 个月一次,随访症状。在 209 例患者中,57 例(27%)为迷走性 AF,14 例(7%)为肾上腺素性 AF,138 例(66%)为随机性 AF。迷走性触发因素为睡眠(96.4%)、餐后(96.4%)、运动后晚期(51%)、冷刺激(20%)、咳嗽(7%)和吞咽(2%)。在 APVI 时,94.3%的患者所有静脉均被隔离。25 例(12%)患者需要进行第二次 APVI。随访 21 +/- 15 个月时,迷走组无 AF 患者的比例为 75%,肾上腺素组为 86%,随机组为 82%(P = 0.51)。
在无结构性心脏病的 PAF 患者中,约有四分之一存在迷走性 AF。APVI 对迷走性 AF 患者与肾上腺素性和随机性 AF 患者同样有效。